PharmacoEconomics & Outcomes News 877, p17 - 1 May 2021

Remdesivir cost effective for severe COVID-19 in China

Remdesivir given for 5 days is a cost-effective treatment for patients hospitalised with severe COVID-19 in China, according to a study published in the *British Journal of Clinical Pharmacology*.

The study used a dynamic compartment transmission model to evaluate the cost effectiveness of remdesivir given for 5 days, compared with standard of care, for the treatment of patients hospitalised with severe COVID-19. The base-case analysis assumed an acquisition cost of ¥16 600 (\$US2340) for the 5-day remdesivir treatment course. The analysis was conducted from the perspective of the healthcare system in China.

The model projected that 5 days of treatment with remdesivir was associated with a net gain of 6947 quality-adjusted life-years (QALYs) over the 55-day time horizon at an incremental cost of \$97.93 million (year 2020 value). The incremental cost-effectiveness ratio for remdesivir was \$14 098 per QALY gained. This value is substantially lower than the commonly accepted cost-effectiveness threshold of $1 \times \text{GDP}$ per capita per QALY gained (\$70 892 [\$US10276] in China in 2019). Furthermore, the maximum number of severe cases per day was substantially lower for the remdesivir strategy, compared with standard of care ($\$163 \times \10082), corresponding to 19% lower hospital-bed requirement to accommodate all severe cases. The results were robust in alternative epidemiological scenarios but were sensitive to changes in effectiveness estimates. A probabilistic sensitivity analysis showed that the 5-day remdesivir regimen had a 98% probability of being cost effective. "Ensuring access to remdesivir in China may benefit the healthcare system when confronted with potential re-surges," conclude the researchers.

Jiang Y, et al. Economic evaluation of remdesivir for the treatment of severe COVID-19 patients in China under different scenarios. British Journal of Clinical Pharmacology: 14 Apr 2021. Available from: URL: http://doi.org/10.1111/bcp.14860